The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s filgrastim biosimilars market report forecasts the filgrastim biosimilars market size to grow to $1.33 Billion by 2027, with a CAGR (compound annual growth rate) of almost 9%.

Learn More On The Filgrastim Biosimilars Market Report 2023 – https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Filgrastim Biosimilars Market Size Forecast
The global filgrastim biosimilars market is expected to grow from $0.88 billion in 2022 to $0.95 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The filgrastim biosimilars market is expected to grow from $1.33 billion in 2027 at a CAGR of 8.9%.

North America held the largest filgrastim biosimilars market share, and Middle East was the fastest-growing region in 2022.

Key Filgrastim Biosimilars Market Driver ­– Increase In Production And Awareness By Government Initiatives For The Development Of Biosimilars
The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government’s initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the filgrastim biosimilars market.

Request for A Sample Of The Global Filgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

Key Filgrastim Biosimilars Market Trend – Product Innovation Through Strategic Collaborations
To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in April 2020, Biocon, an India-based biopharmaceutical company, partnered with Mylan, a US-based generic and specialty pharmaceuticals company, to introduce Fulphila, a biosimilar pegfilgrastim, in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.

Filgrastim Biosimilars Market Segment
1) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Applications
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing Organizations

 Filgrastim Biosimilars Market Major Players and Strategies
Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon, and Aryogen Biopharma.

In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, acquired Viatris Inc. for $3.3 billion. This acquisition would build a distinctive, fully integrated, global biosimilars enterprise. This strategic alliance combines the strengths and complementary skills of both parties, positioning Biocon Biologics for the next ten years of value generation for all of our stakeholders. Viatris Inc. is a US-based pharmaceutical company that has developed a biosimilar of pegfilgrastim.

The Filgrastim Biosimilars Global Market Report 2023 covers regional data on filgrastim biosimilars market size, filgrastim biosimilars market trends and drivers, opportunities, strategies, and filgrastim biosimilars market competitor analysis. The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.

View More Reports Related To The Filgrastim Biosimilars Market –
Pegfilgrastim Biosimilars Global Market Report 2023
Biosimilars Global Market Report 2023
Trastuzumab Biosimilars Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: